Raloxifene hydrochloride
Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen
Grundinformationen
- CAS
82640-04-8- Standard-SMILES
O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12.[Cl-].[H+]- InChIKey
BKXVVCILCIUCLG-UHFFFAOYSA-N- Summenformel
- C28H28ClNO4S
- Durchschnittliche Molmasse
- 510,04 g/mol
Namen und Bezeichner
- Bevorzugter Name
- Raloxifene hydrochloride
- Englischer Name
- Raloxifene hydrochloride
- Summenformel
- C28H28ClNO4S
- Molmasse
- 510.04
Namen und Synonyme
RALOXIFENE HCL(6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl)(4-(2-(piperidin-1-yl)ethoxy)phenyl)Methanone hydrochlorideCS-127ly156758KEOXIFENELY 139481AKOS 92138RALOXFENE HCLLY156758 hydrochlorideLY139481 hydrochloride
Datenbank-Bezeichner
- CAS
82640-04-8- PubChem CID
- 25010765
Eigenschaften
Physikochemische Eigenschaften
- Schmelzpunkt
- 250 · 250-253°C
- storage temp.
- 2 · 2-8°C
- Löslichkeit
- 28 mg/mL, · DMSO: 28 mg/mL, soluble
- Aggregatzustand
- solid
- Farbe
- light yellow
- Merck
- 14 · 14,8098
- BCS Class
- 2 · 2
- Major Application
- pharmaceutical (small molecule)
- InChI
- 1S/C28H27NO4S.ClH/c30-21-8-4-20(5-9-21)28-26(24-13-10-22(31)18-25(24)34-28)27(32)19-6-11-23(12-7-19)33-17-16-29-14-2-1-3-15-29;/h4-13,18,30-31H,1-3,14-17H2;1H
- InChIKey
- BKXVVCILCIUCLG-UHFFFAOYSA-N
- SMILES
- C1(C(=O)C2C=CC(OCCN3CCCCC3)=CC=2)C2C=CC(O)=CC=2SC=1C1C=CC(O)=CC=1.Cl
- CAS Datenbank
- 82640 · 82640-04-8(CAS DataBase Reference)
Sicherheit und Regulatorisches
Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
Sicherheitsdaten
- wgk
- 3
- hs_code
- 2934990002
- RTECS-Nr.
- PC4956925
- risk_code
- 36/37/38
- hazard_code
- Xi
- safety_code
- 22-24/25
- Speicherklasse
- 11 - Combustible Solids
- Hazard Classifications
- Carc. 2Repr. 2
Chemie und Industrie
Anwendungen
BeschreibungRaloxifene was launched as Evista in the US for the prevention of postmenopausal osteoporosis. It is noteworthy that this molecule was formerly under development as keoxifene for breast cancer and prostatic hypertrophy. Raloxifene can be prepared by acylation of 6-methoxy-2-(4-methoxyphenyl) benzothiophene followed by simultaneous demethylation of both methoxy groups. Raloxifen is a selective estrogen receptor modulator, exerting antiestrogenic action on certain tissues (breast) and also estrogenic action on bone metabolism or serum lipids. In normal early postmenopausal women, 200 mg daily produced a trend towards suppression of estrogen effects. Raloxifen impeded bone loss in osteoporosis. A two-year study in postmenopausal women with an increased risk for osteoporosis showed that Raloxifen markedly prevented non-traumatic vertebral fractures. Results of several clinical studies demonstrated that Raloxifen appreciably reduced the risk of developing breast cancer. Moreover, it had favourable effect on lipid profiles without having the potential side-effects of estrogen-based therapies. Several extensions for different uses of this molecule are planned, for example growth disorder, obesity, colon tumor and skin atrophy. No serious drug-related events have been reported in the limited number of clinical trials.
VerwendenRaloxifene hydrochloride can be used as a nonsteroidal, selective estrogen receptor modulator (SERM). Antiosteoporotic.
Vor- und nachgelagerte Produkte
Vorgelagerte Rohstoffe
Nachgelagerte Produkte
Zugehörige Reaktionen
0
Keine Reaktionsaufzeichnungen unter den aktuellen Filterkriterien.
Notizen zur Verbindung
Wird geladen…